Life sciences · Interventional Study
ClinicalTrials.gov · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT03723928). This is a study registration, not published results. Lead sponsor: SWOG Cancer Research Network. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 739 participants (ESTIMATED). Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29. Interventions: OTHER: Usual care disease monitoring; OTHER: Serum Tumor Marker directed disease monitoring; OTHER: Quality-of-Life Assessment; OTHER: Anxiety Questionnaire Administration. Primary outcome measures: Assessment of whether patients monitored with STMDDM have non-inferior overall survival compared with patients monitored with usual care , Up to 312 weeks after randomization. Brief summary: This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.